Insights into Recent Transactions of Genmab's Management Team

Author: Dylan Bailey Updated: 09-09-2025 03:00 PM

Understanding Managerial Transactions at Genmab A/S

Company Announcement

COPENHAGEN, Denmark; An important update from Genmab A/S (Nasdaq: GMAB) informs us about transactions made by its managerial employees and their closely associated persons. This disclosure follows the regulations outlined in Article 19 of Regulation No. 596/2014.

Genmab places a high priority on transparency, empowering its managerial employees and their associates to allow the company to make their trading activities public. This decision emphasizes Genmab’s commitment to ethical practices in corporate governance.

About Genmab A/S

Genmab is an internationally recognized biotechnology firm focused on crafting innovative antibody therapeutics. Thanks to its dedicated team, Genmab has remained at the forefront of biomedical advancements for more than 25 years. Their groundbreaking intellect has led to the creation of sophisticated antibody technology platforms while employing cutting-edge data science for product development.

The company’s pledge is to transform patient care through state-of-the-art antibody medicines by 2030. Their vision, expressed as "knock-your-socks-off (KYSO) antibody medicines,” seeks to deliver life-changing treatments for individuals battling cancer and serious diseases.

Company Highlights

Since its inception in 1999, Genmab A/S has anchored itself in Copenhagen with a significant presence in North America, Europe, and the Asia-Pacific region. This diverse geographical footprint enhances its ability to connect with various stakeholders and facilitates efficient global operations.

By consistently pushing the envelope in antibody treatment solutions, Genmab not only garners recognition but also sets aspiring benchmarks in the biotechnology industry.

Managerial Staff Contacts

For further inquiries, two key representatives at Genmab can be contacted: Marisol Peron, Senior Vice President of Global Communications, and Andrew Carlsen, Vice President focusing on Investor Relations. They are reachable via their direct phone lines and corporate email addresses.

If you're interested in knowing more about Genmab's strategies or product lines, feel free to reach out for the latest updates.

Frequently Asked Questions

What type of transactions are disclosed by Genmab's management?

These transactions include trading activities executed by managerial employees and their closely associated entities, emphasizing transparency.

How does Genmab ensure transparency in its operations?

Genmab empowers its managerial staff to disclose their trading activities to maintain high standards of corporate governance and transparency.

What sectors does Genmab focus on?

Genmab specializes in biotechnology, particularly in developing innovative antibody therapeutics targeting cancer and serious diseases.

How can I stay updated on Genmab's news?

Visit Genmab's official website or follow their social media channels for the latest updates and announcements.

Who should I contact for investor relations inquiries?

For investor relations matters, you can reach Andrew Carlsen at Genmab, who can assist with your queries.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.